Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

High Risk

Score: 90/100

Failure Rate

33.3%

2 terminated/withdrawn out of 6 trials

Success Rate

60.0%

-26.5% vs industry average

Late-Stage Pipeline

17%

1 trials in Phase 3/4

Results Transparency

0 of 3 completed trials have results

Key Signals

Enrollment Performance

Analytics

Phase 2

3(60.0%)

Phase 1

1(20.0%)

Phase 4

1(20.0%)

5Total

Phase 2(3)

Phase 1(1)

Phase 4(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (6)

Showing 6 of 6 trials

NCT00615706Completed

Study to Evaluate the Impact of Obesity on Airway Inflammation and Mechanics in Asthmatics

Role: collaborator

NCT00486343Phase 4Terminated

Zileuton CR vs Placebo in Poorly Controlled Asthma Patients on Moderate Dose ICS

Role: lead

NCT00534625Phase 2Completed

Assessment of PFT, Safety, and PK of Zileuton Injection in Asthma Patients

Role: lead

NCT00299065Phase 1Completed

Safety Study of Zileuton Injection in Patients With Asthma

Role: lead

NCT00098358Phase 2Unknown

Study of Oral Zileuton in the Treatment of Moderate to Severe Facial Acne Vulgaris

Role: lead

NCT00107666Phase 2Terminated

CTI-01 (Ethyl Pyruvate) Safety and Complication Prevention in Cardiac Surgery Patients on Cardiopulmonary Bypass (CPB)

Role: lead

All 6 trials loaded